IRCT2017070234844N1
Recruiting
Phase 2
Comparing the Atomoxetine effectiveness in retention of patients in the stimulant (Meth-Amphethamine) dependence treatment with placebo in a three month period
Tehran University of Medical Sciences (TUMS), Vice-chancellor for Research0 sites90 target enrollmentTBD
ConditionsOther stimulants dependence syndrome.Dependence syndrome: A cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despiteF15.24
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Other stimulants dependence syndrome.
- Sponsor
- Tehran University of Medical Sciences (TUMS), Vice-chancellor for Research
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\- Diagnosis of methamphetamine use disorder based on DSM\-5; 2\- Using methamphetamine 2 times or more in week during last month; 3\- Age: 18 to 60 years old; 4\. Referring to Psychiatric Clinic of Roozbeh Hospital or Iranian National Center for Addiction Studies (INCAS) Clinic
- •Exclusion criteria:
- •1\. Sensitivity to Atomoxetine; 2\. Rising liver enzymes more than three times; Hepatic failure, acute hepatitis; 3\. Other substance use disorders including alcohol, opioids and sedative and hypnotic medications (except nicotine); 4\. More than 2 times illicit opioid use during last month; 5\. Use of mono\-amine oxidase inhibitor (MAOI) medications during last 2 weeks; 6\. Severe cardiac disorder, history of MI during last month, uncontrolled hypertension (HTN); 7\.Pregnancy or breastfeeding; 8\. Risk of suicide, homicide or violence; 9\. Psychosis; 10\.
- •Unable to comprehend study protocol and answer questionnaires; 11\. Receiving
- •opioid agonist medications such as MMT.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophreniaIRCT20101130005280N31Mashhad University of Medical Sciences42
Completed
Phase 2
?Effects of Atomoxetine and Trazodone combination in obstructive sleep apneaobstructive sleep apnea.Obstructive sleep apnea (adult) (pediatric)G47.33IRCT20220607055095N1Tehran University of Medical Sciences18
Recruiting
Phase 1
Y139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese SubjectsAttention Deficit Hyperactivity DisorderJPRN-jRCT1080221208Eli Lilly Japan K.K.
Recruiting
Phase 3
Evaluating the effect of Atomoxetine and Oxybutynin combination on the number of apnea in obstructive sleep apnea patients referring to the sleep clinics of Tehran University of Medical SciencesObstructive Sleep Apnea.Obstructive sleep apnea (adult) (pediatric)G47.33IRCT20220201053905N1Tehran University of Medical Sciences18
Completed
Not Applicable
Treatment of social anxiety disordersocial phobia.Social phobiasIRCT201102035750N1Vice-chancellor for research of Tehran univesity of medical sciences30